建立分级分层新闻发布制度。坚持国家和地方相结合、现场发布与网上发布相结合，建立多层次多渠道多平台信息发布机制，持续发布权威信息，及时回应国内外关注的疫情形势、疫情防控、医疗救治、科研攻关等热点问题。截至5月31日，国务院联防联控机制、国务院新闻办公室共举行新闻发布会161场，邀请50多个部门490余人次出席发布会，回答中外媒体1400多个提问；湖北省举行103场新闻发布会，其他省份共举行1050场新闻发布会。

　　依法适时订正病例数据。本土疫情得到控制后，为确保公开透明、数据准确，武汉市针对疫情早期因收治能力不足导致患者在家中病亡、医院超负荷运转、死亡病例信息登记不全等原因，客观上存在迟报、漏报、误报现象，根据相关法律规定，在深入开展涉疫大数据与流行病学调查的基础上，对确诊和死亡病例数进行了订正，并向社会公开发布。

A tiered news release mechanism has been formed.At both national and local levels, a tiered information release mechanism has been formed to circulate authoritative information through various channels and platforms, both onsite and online, in order to address domestic and international concerns on virus control, medical treatment, and scientific research. By May 31, the Joint Prevention and Control Mechanism and the Information Office of the State Council had held 161 press conferences during which officials from more than 50 government departments appeared over 490 times and answered more than 1,400 questions from Chinese and foreign media. One hundred and three press conferences had been held in Hubei and 1,050 in the other provinces.

Covid-19 statistics have been updated in accordance with the law.In the early stage of Covid-19 control, there were late, incomplete and erroneous reports of Covid-19 cases in Wuhan due to unverified deaths at home, inadequate hospital capacity, hospitals being overwhelmed, and incomplete recording of deaths. After the domestic spread of Covid-19 had been brought under control, the city updated the number of confirmed cases and deaths based on big data application and an epidemiological investigation to ensure accuracy of the data, and released the results in an open and transparent manner in accordance with the law.

　　多渠道多平台传播信息。国家卫生健康委中、英文官方网站和政务新媒体平台设置疫情防控专题页面，发布每日疫情信息，解读政策措施，介绍中国抗疫进展，普及科学防控知识，澄清谣言传言。各省（自治区、直辖市）政府网站及政务新媒体平台及时发布本地疫情信息和防控举措。大力开展应急科普，通过科普专业平台、媒体和互联网面向公众普及科学认知、科学防治知识，组织权威专家介绍日常防控常识，引导公众理性认识新冠肺炎疫情，做好个人防护，消除恐慌恐惧。加强社会舆论引导，各类媒体充分传递抗击疫情正能量，同时发挥舆论监督作用，推动解决疫情防控中出现的问题。

Covid-19-related information is provided through various channels and platforms.The NHC’s official Chinese and English websites and its social media platform have special sections where Covid-19-related information is released on a daily basis, including information on relevant policies, progress in China’s containment efforts, updates on disease prevention and control, and clarifications that refute rumors. Information on local Covid-19 control has been promptly released on government websites and social media platforms of all provinces. To disseminate knowledge about its Covid-19 response, China has released relevant information through platforms for popularizing science, and through the media and the internet. Leading medical experts have offered advice on routine self-protection to help the public see Covid-19 in a rational way and forestall panic. The media has expanded public outreach and sent a positive message in combating the virus, and public opinion has played its role of oversight to help solve problems affecting virus control.

　　（五）充分发挥科技支撑作用

　　科学技术是人类同疾病较量的锐利武器，人类战胜大灾大疫离不开科学发展和技术创新。面对人类未知的新冠病毒，中国坚持以科学为先导，充分运用近年来科技创新成果，组织协调全国优势科研力量，以武汉市为主战场，统筹全国和疫情重灾区，根据疫情发展不同阶段确定科研攻关重点，坚持科研、临床、防控一线相互协同和产学研各方紧密配合，为疫情防控提供了有力科技支撑。

5.Science and Technology Underpin China’s Efforts

Science and technology are the sharp blade that humanity wields in the battle against disease. Such battles could not have been won without scientific advances and technological innovation. Confronted by Covid-19, a previously unknown virus, China has exploited the pioneering role of science and technology and fully applied the results of scientific and technical innovation in recent years. Top scientific research resources have gathered from around the nation to support virus control. Focusing on the main battlefield of Wuhan and coordinating efforts in the most severely-affected areas and across the rest of the country, China pinpointed key R&D areas for different stages of virus control. The close coordination between scientific research, clinical application, and frontline virus control, and between enterprises, universities, and research institutes, has given powerful support for the war against the virus.

　　实施科研应急攻关。遵循安全、有效、可供的原则，加快推进药物、疫苗、新型检测试剂等研发和应用。适应疫情防控一线的紧迫需求，围绕“可溯、可诊、可治、可防、可控”，坚持产学研用相结合，聚焦临床救治和药物、疫苗研发、检测技术和产品、病毒病原学和流行病学、动物模型构建5大主攻方向，组织全国优势力量开展疫情防控科技攻关，加速推进科技研发和应用，部署启动83个应急攻关项目。按照灭活疫苗、重组蛋白疫苗、减毒流感病毒载体疫苗、腺病毒载体疫苗、核酸疫苗等5条技术路线开展疫苗研发。目前，已有4种灭活疫苗和1种腺病毒载体疫苗获批开展临床试验，总体研发进度与国外持平，部分技术路线进展处于国际领先。组织科研团队开展科学溯源研究。

Key progress has been made in scientific research.Following the principles of safety, effectiveness and availability, China has accelerated the R&D and application of medicines, vaccines, and new test kits. To meet the urgent needs of frontline virus control, and to ensure traceability of infection sources, diagnosis and treatment of patients, and prevention and control of infections, China has pooled resources from enterprises, universities, and research institutes, directing them to focus on five areas – clinical treatment, new medicines and vaccines, testing techniques and products, viral etiology and epidemiology, and animal model construction. Top research resources from around the nation have been galvanized to work on these tasks in pursuit of early results and application. A total of 83 emergency R&D programs have been initiated. Vaccines are being developed in five categories – inactivated vaccines, recombinant protein vaccines, live attenuated influenza vaccines, adenovirus vaccines, and nucleic acid-based vaccines. To date, four inactivated vaccines and one adenovirus vaccine have been approved for clinical trials. While scientists in China and abroad have kept up with mutual developments, China leads the world in the development of certain types of vaccines. Research teams have also been assembled to trace the origin of Covid-19.

　　坚持科研攻关和临床救治、防控实践相结合。第一时间研发出核酸检测试剂盒，推出一批灵敏度高、操作便捷的检测设备和试剂，检测试剂研发布局涵盖核酸检测、基因测序、免疫法检测等多个技术路径。坚持“老药新用”基本思路，积极筛选有效治疗药物，探索新的治疗手段，在严谨的体外研究和机制研究基础上，不断总结救治经验，推动磷酸氯喹、恢复期血浆、托珠单抗和中医药方剂、中成药等10种药物或治疗手段进入诊疗方案，获得4项临床批件，形成5项指导意见或专家共识。开展试验性临床治疗，加快推广应用临床验证有效的诊疗方法和药物。强化实验室生物安全监管，加强新冠病毒临床检测血液样本和实验室检测生物样本管理。

Scientific R&D has been integrated with clinical treatment and epidemic control.Having promptly developed nucleic acid test kits, China has also introduced a range of high-sensitivity, easy-to-use test equipment and reagents. Its R&D of reagents covers nucleic acid testing, gene testing, and immunological testing.

Putting existing medicines to new use, China has searched for effective medicines and new therapies, and summarized clinical experience based on rigorous in vitro experiments and pathogenic research. Ten types of medicine, including chloroquine phosphate, tocilizumab, finished TCM drugs, and herbal preparations, as well as convalescent plasma therapy, have been adopted in treatment plans. Approval for clinical trial has been given to four medicines, and guidelines formed or expert consensus reached in five areas. Clinical treatments have been trialed, and diagnosis and treatment methods and medicines that have proven clinically effective have been rolled out at a faster pace. Biosecurity has been strengthened at laboratories, as has the management of blood samples for Covid-19 testing and biological samples for laboratory testing.